Figures & data
Figure 1. In case 1, CT images showed a continuously increase of the lung metastases during multi-anti-HER2 targeted therapy and a remarkable decrease after treatment of pembrolizumab plus albumin-bound paclitaxel with the reduction of serum HER2 ECD levels.
Figure 2. In case 2, CT images showed a continuously increase of the right chest wall metastasis during multi-anti-HER2 targeted therapy and a remarkable decrease after treatment of pembrolizumab plus albumin-bound paclitaxel with the reduction of serum HER2 ECD levels.
Figure 3. The immunohistochemistry results showed PD-Ll and PD-1 expression of the tumor sample (formalin-fixed paraffm-embedded specimens) obtained from Case 1 patient with a proportion score of less than 1% (A and B), from Case 2 patient also with a proportion score of less than 1% (C and D) at a magnification of 200.
